Bank of New York Mellon Corp Has $1.25 Million Position in REGENXBIO Inc. (NASDAQ:RGNX)

Bank of New York Mellon Corp cut its stake in REGENXBIO Inc. (NASDAQ:RGNX) by 49.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 161,136 shares of the biotechnology company’s stock after selling 159,253 shares during the period. Bank of New York Mellon Corp’s holdings in REGENXBIO were worth $1,246,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the stock. GAMMA Investing LLC lifted its position in REGENXBIO by 273.1% during the fourth quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 2,510 shares during the period. FMR LLC raised its position in shares of REGENXBIO by 166.8% in the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 1,656 shares in the last quarter. Erste Asset Management GmbH bought a new stake in shares of REGENXBIO during the 3rd quarter worth approximately $140,000. Intech Investment Management LLC acquired a new stake in shares of REGENXBIO during the 3rd quarter worth approximately $161,000. Finally, BNP Paribas Financial Markets increased its stake in REGENXBIO by 602.9% in the third quarter. BNP Paribas Financial Markets now owns 20,441 shares of the biotechnology company’s stock valued at $214,000 after acquiring an additional 17,533 shares during the last quarter. 88.08% of the stock is currently owned by institutional investors.

REGENXBIO Stock Performance

Shares of NASDAQ:RGNX opened at $8.24 on Monday. REGENXBIO Inc. has a 52 week low of $5.62 and a 52 week high of $22.42. The firm has a market cap of $412.71 million, a PE ratio of -1.64 and a beta of 1.35. The firm’s fifty day moving average is $7.30 and its 200-day moving average is $8.87.

REGENXBIO (NASDAQ:RGNX) last announced its earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) EPS for the quarter, beating the consensus estimate of ($1.27) by $0.26. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. The business had revenue of $21.21 million for the quarter, compared to analysts’ expectations of $23.70 million. Sell-side analysts forecast that REGENXBIO Inc. will post -4.84 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently weighed in on RGNX shares. Morgan Stanley upped their price objective on REGENXBIO from $22.00 to $24.00 and gave the stock an “overweight” rating in a research report on Friday, March 14th. Chardan Capital restated a “buy” rating and issued a $52.00 price target on shares of REGENXBIO in a research note on Thursday. Royal Bank of Canada reaffirmed an “outperform” rating and set a $30.00 price target on shares of REGENXBIO in a report on Tuesday, January 21st. Raymond James assumed coverage on shares of REGENXBIO in a research note on Friday, February 7th. They issued an “outperform” rating and a $27.00 price objective for the company. Finally, HC Wainwright decreased their target price on shares of REGENXBIO from $36.00 to $34.00 and set a “buy” rating on the stock in a research note on Monday, March 17th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $33.88.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.